Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: September 3, 2025
Reporting Period: Event-based report for September 3, 2025
Business Overview: The Company is a Delaware corporation focused on medical diagnostics, specifically highlighting its CyPath® Lung test for lung cancer detection.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K reports a corporate event rather than financial results.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses on a specific corporate announcement regarding media coverage.
Guidance, Outlook, and Management Commentary
- Media Recognition: On September 3, 2025, the Company announced that U.S. Medicine Magazine featured its CyPath® Lung test in its pulmonary issue.
- Strategic Focus: The feature highlighted the test's potential to improve lung cancer detection and lower costs for the Department of Veterans Affairs (VA).
- Exhibits: A copy of the press release is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific details on the U.S. Medicine Magazine feature.
- Confirm the current trading status of Common Stock (BIAF) and Warrants (BIAFW) on the Nasdaq Capital Market.
- Review subsequent filings for any updates on the Department of Veterans Affairs (VA) engagement or commercialization progress of CyPath® Lung.
- Check the Company's latest 10-Q or 10-K for actual financial performance data, as this 8-K contains no financial statements.